Haleon plc
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brian James McNamara
- Full Time Employees
- 24,561
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Building 5 Weybridge United Kingdom KT13 0NY
- IPO Date
- Jul 25, 2022
- CIK
- 0001900304
- Website
- haleon.com
- Similar Companies
- Business
- Haleon plc operates as a leading consumer healthcare company focused on everyday health products across six core categories: oral health, vitamins minerals and supplements (VMS), pain relief, respiratory health, digestive health, and therapeutic skin health; its portfolio features market-leading brands such as Sensodyne, Parodontax and Polident for toothpaste, denture care and gum health; Centrum, Emergen-C and Caltrate for multivitamins, vitamin C and calcium supplements; Advil, Panadol and Voltaren for pain relief and anti-inflammatory treatments; Otrivin, Theraflu, Flonase, Contac and Beechams for cold, flu, nasal congestion, coughs and allergies; Tums, ENO and Benefiber for heartburn, acid indigestion and fiber supplementation; and Fenistil, Zovirax and Bactroban for skin treatments. The company, founded through a 2022 spin-off from GlaxoSmithKline's consumer healthcare business and tracing roots to 1715, maintains headquarters in Weybridge, England, and conducts operations in over 170 markets worldwide, including key segments in North America, Europe Middle East Africa and Latin America (EMEA & LatAm), and Asia Pacific (APAC), serving more than one billion consumers and health professionals. Haleon plc recently completed the acquisition of the remaining 12% equity interest in its China joint venture Tianjin TSKF Pharmaceutical Co Ltd in June 2025 for approximately 200 million pounds, establishing TSKF as a wholly owned subsidiary that manufactures and distributes brands like Fenbid, Voltaren and Bactroban and represented about 40% of its China revenues in 2024; earlier in September 2024 it finalized the divestiture of its non-US nicotine replacement therapy business to Dr Reddy's Laboratories for 458 million pounds upfront plus up to 42 million pounds in contingent payments; and in March 2025 Pfizer fully exited its remaining stake for about 2.5 billion pounds following prior reductions.
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities
Haleon Issues Voluntary Nationwide Recall of Gas-X Extra Strength Softgels 125mg, 120 ct. and 72 ct.
Haleon plc (HLN) Presents at 23rd annual dbAccess Global Consumer Conference Transcript
TUMS Kicks Off the "TUMS Food Match Cup," a Celebration of Global Soccer Fandom and Food Love Through Bold Flavor Mashups
LCUT vs. HLN: Which Stock Is the Better Value Option?
‘For The Assist': Haleon Canada launches national campaign with Canada Soccer to celebrate the small health supports behind Canadian wellbeing
LCUT or HLN: Which Is the Better Value Stock Right Now?
Haleon performance might be stronger than you think, analyst repeats 'buy' rating
Centrum Launches Newly Reformulated Adults 50+ Complete Multivitamin with Clinically Shown Cognitive Benefits
Haleon plc (HLN) Q1 2026 Sales/Trading Call Transcript
Haleon hit by weak cold season but strong toothpaste sales keep outlook on track
Ecora Royalties reveals "solid start" to year
Helium One hires Clive Carver to be new chairman
Futura Medical refines strategy and evolves commercial model after tough 2025
London BTC Company launches search for US gold assets
Haleon Launches For the Assist Campaign in Partnership with the U.S. Soccer Federation Featuring Stars Tyler Adams and Crystal Dunn
Haleon Appoints Richard Manso as US Chief Marketing Officer to Advance Data-driven, Consumer-centric Marketing in Delivering Better Everyday Health
Eagle Global Advisors LLC Boosts Stake in Haleon PLC Sponsored ADR $HLN
What Makes Haleon PLC Sponsored ADR (HLN) a New Buy Stock
Haleon PLC Sponsored ADR (NYSE:HLN) Given Average Rating of “Moderate Buy” by Brokerages